CAI - Company ID 0002019410
Caris Life Sciences, Inc. trades as CAI and has a market capitalization of $5.05 B, making it the #1412 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $812.03M, up 97.0% from the prior year and net income of -$68.09M. This page tracks Caris Life Sciences, Inc. through 102 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -111.5% to -8.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-05-12 |
Revenue growth of 79% driven by strong performance in molecular profiling services
The largest companies sharing Caris Life Sciences, Inc.'s SEC industry classification (services-medical laboratories).
Caris Life Sciences, Inc. (CAI) has a market capitalization of $5.05 B as of 2026-07-09, ranking #1412 among US-listed companies.
Caris Life Sciences, Inc. reported revenue of $812.03M for fiscal year 2025, an increase of 97.0% year over year.
In its latest fiscal year Caris Life Sciences, Inc. reported a net loss of $68.09M.